Nureca Ltd. · NSE:NURECA
Nureca — Q1 FY2022 Earnings Presentation
23 slides from Nureca's earnings presentation, July 2021
Slide 1: Q1FY22 Earnings Presentation
NURECA Q1FY22 Earnings Presentation Q1FY22 Earnings Presentation
Slide 2: Disclaimer
DISCLAIMER The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Our Focus Areas
Our Focus Areas NURECA, IS A LEADING DIGITAL HEALTHCARE CHRONIC DISEASES LIFESTYLE & FITNESS AND WELLNESS SOLUTIONS PROVIDER ORTHOCARE MOTHER & BABY NUTRITION 2021 ₹ 163CR ₹ 119CR 50+ Listed On Stock GMV For Q1FY22 Revenue For Q1FY22 USFDA Approved Products Exchanges ₹ 49CR 03 150SKUS ₹ 155CR Q1FY22
Slide 4: Management Commentary - Aryan Goyal
MANAGEMENT COMMENTARY “ ARYAN GOYAL Founder and CEO Our brands – Dr Trust, Dr Physio and Trumom have grown exceptionally over the past few years and now enjoy higher credibility and pull on all the digital channels. We were able to grow a large loyal customer base in a relatively short period of tim
Slide 5: Management Commentary - Saurabh Goyal
MANAGEMENT COMMENTARY “ SAURABH GOYAL Managing Director Over the last decade, rising income and standard of living has led to increase in lifestyle related chronic deceased. Although, advancement in medical technology has made it possible to treat these chronic deceases, it remains very expensive fo
Slide 6: Our Growing Customer Base
OUR GROWING CUSTOMER BASE CUSTOMER BASE (CUMULATIVE)* STEADY IMPROVEMENT IN REPEAT CUSTOMER (000’) 132% CAGR Returning visitors to our website 8,865 8,021 20% 4,639 17% 713 Q1FY22 Earnings Presentation FY19 FY20 FY21 FY22 (as of Mar-21 Jun-21 Jun-21) Our customer base has grown exceptionally over th
Slide 7: Evolving Regulatory Landscape
EVOLVING REGULATORY LANDSCAPE RECENT CHANGES IN REGULATION § The National Pharmaceutical Pricing Authority (NPPA) has capped the price of five medical devices namely Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer and Glucometer under “Trade Margin Rationalisation A
Slide 8: Operational and Financial Highlights
OPERATIONAL OUR DIGITAL DNA HELPED US SAIL THROUGH DEADLY HIGHLIGHTS SECOND WAVE OF COVID-19 § Digital DNA of our company helped us continue our operations FINANCIAL HIGHLIGHTS uninterrupted, illustrating the resilience of our unique business model § COVID-19 has changed the healthcare ecosystem wit
Slide 9: Key Performance Indicators: GMV and Operating Revenue
KEY PERFORMANCE INDICATORS STRONG GMV GROWTH (INR mn) 285% • Operating Revenue surged 4x as compared to 1,627 Q1FY21 driven by strong demand for medical 1,404 products, launch of new SKUs and sustainable movement of demand from offline channels to 735 online channels 423 433 • New product launched d
Slide 10: Key Performance Indicators: EBITDA and PAT
KEY PERFORMANCE INDICATORS ROBUST EBITDA & EBITDA MARGIN • EBITDA increase by 3.7x as compared to Q1FY21 (INR mn) • EBITDA Margin remain stable on YoY basis due to 492 higher employee cost whereas on QoQ basis 43% 40% 40% margin expanded 2,342 BPS 369 • Q1FY22 was affected second wave of COVID-19 in
Slide 11: Key Performance Indicators: EPS and Return Ratios
KEY PERFORMANCE INDICATORS EPS CONTINUES TO GROW • EPS stood at Rs. 36.2 as compared to Rs. 13.5 in (INR) Q1FY21, a growth of 168% YoY 38 36 • EPS continue to grow on the back of strong Revenue and PAT numbers. 13 • Our products continue to enjoy premium over our 9 competitors due to strong brand lo
Slide 12: Financials – Income Statement
FINANCIALS – INCOME STATEMENT Particulars (INR Mn) Q1FY22 Q1FY21 Y-o-Y (%) Q4FY21 Q-o-Q (%) Revenue from operations 1,194.8 302.2 295.4% 318.4 275.3% Other Income 21.4 1.6 12.8 TOTAL REVENUE 1,216.2 303.8 300.3% 331.2 267.2% Cost of Goods Sold 494.4 96.7 411.1% 164.5 200.6% Employee benefits expense
Slide 13: New Products Launched
NEW PRODUCTS LAUNCHED Q1FY22 Earnings Presentation 13 *Frost & Sullivan
Slide 14: Expanding Our Presence in Wellness and Preventive Healthcare Market
EXPANDING OUR PRESENCE IN WELLNESS AND PREVENTIVE HEALTHCARE MARKET Strong Product Pipeline 1 We launched 8 new products this quarter taking the total SKUs to 150 2 Majority of products launched during the quarter were Nutraceuticals, 202 focusing on dietary supplements to capitalize on higher deman
Slide 15: Expanding Horizons: Nutraceuticals Market
EXPANDING HORIZONS NUTRACEUTICALS MARKET FOR INDIA AND NEIGHBOURING COUNTRIES* (INR Cr) 30,061 27,082 24,399 21,981 By 2023, India is also expected to hold at least 3.5% market share of the global market from current levels of ~2%. Q1FY22 Earnings Presentation FY21 FY22 FY23 FY24 Nutraceutical marke
Slide 16: Competitive Landscape
COMPETITIVE LANDSCAPE Respiratory Care Nebulizer √ √ √ √ x √ Pulse Oximeter √ x x √ x √ Cardiac Care BP Monitor √ √ x √ x √ Heart Rate Monitor √ √ x √ x x Diabetes Care Blood Glucometer √ x x x x √ Niche Categories Q1FY22 Earnings Presentation Massagers √ √ x √ x x Baby Care √ x √ √ x x Others Perso
Slide 17: Healthcare and Wellness Products Opportunity in India
HEALTHCARE AND WELLNESS PRODUCTS OPPORTUNITY IN INDIA AND NEIGHBORING COUNTRIES (INR Cr) 38,880 1,277 R Overall Indian Healthcare and wellness products G 1 CA % market is expected to growth at 11% to INR 38,880cr in .9 10 2025 with Lifestyle products market expected to grow fastest at 14.5% CAGR. 20
Slide 18: Opportunity Landscape
OPPORTUNITY LANDSCAPE CHRONIC DISEASE PRODUCTS MARKET ORTHOPEDIC PRODUCTS MARKET (INR Cr) (INR Cr) R C AG 1,163 C AGR 2,513 10. 9% 9.3% 683 1,357 Q1FY22 Earnings Presentation 2019 2025 2019 2025 Increasing Chronic diseases contribution to the deaths, The growth in this market is primarily driven by
Slide 19: What Makes Nureca Different?
WHAT MAKES NURECA DIFFERENT? Product Quality • International standards quality and design of the products Regulatory Compliance • Our products are manufactured to be safe, accurate, long-lasting and compliant to national and international regulations. Our chronic monitoring devices are USFDA approve
Slide 20: Business Outlook
BUSINESS OUTLOOK • Strong focus on connected devices for remote patient monitoring ADDING PRODUCTS AND • Expansion into supplement and nutrition categories CATEGORIES • Create a pipeline of innovative healthcare and wellness products • A strong customer base for cross-selling of different products •
Slide 21: Use of IPO Proceeds
USE OF IPO PROCEEDS The Net Proceeds are utilized in accordance with the details provided in the following table: (INR Mn) Planned proceeds as Utilization upto Unutilized amount as Objectives as per Prospectus Actual proceeds per Prospectus 30 June 2021 on 30 June 2021 Funding incremental working Ca
Slide 22: Shareholder Information
SHAREHOLDER INFORMATION SHARE INFORMATION (AS ON 30TH JULY 2021) SHAREHOLDING AS ON 30TH JUNE 2021 NSE Ticker NURECA Others BSE Ticker 543264 12.1% IPO Listing Date 25th February 2021 AIF & Financial Share Price (INR) 1,725 Institutions 5.4% Market Cap (INR Cr) 1,725 Mutual Funds % free-float 25.00%
Slide 23: Thank You
INVESTOR RELATIONS AT NURECA Gurvikram Singh cs@nureca.com CHRISTENSEN ADVISORY Rahul Thakur rthakur@christensenir.com Q1FY22 Earnings Presentation THANK YOU… 23